BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present next week at the Influenza Vaccines for the Worldconference in Edinburgh, Scotland, UK.

Joshua Phillipson, BiondVax’s Head of Business Development, will provide an overview of the Company’s achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial.

Details of Mr. Phillipson’s presentation:

Getting Closer to the Market: BiondVax’s Universal Flu Vaccine Pivotal Phase 3 Trial

Date: Tuesday, April 2, 2019

Location: Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK

Those interested in meeting with Mr. Phillipson are invited to contact him at j.phillipson@biondvax.com.

About BiondVax

BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. BiondVax’s proprietary technology utilizes a unique combination of conserved and common influenza virus peptides intended to stimulate both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity. Please visit www.biondvax.com.